Kuang Liwen, Wu Lei, Li Yongsheng
School of Medicine, Chongqing University, Chongqing, China.
Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, China.
Mol Cancer. 2025 Feb 14;24(1):45. doi: 10.1186/s12943-025-02233-w.
Extracellular vesicles (EVs), nanoscale vesicles secreted by cells, have attracted considerable attention in recent years due to their role in tumor immunomodulation. These vesicles facilitate intercellular communication by transporting proteins, nucleic acids, and other biologically active substances, and they exhibit a dual role in tumor development and immune evasion mechanisms. Specifically, EVs can assist tumor cells in evading immune surveillance and attack by impairing immune cell function or modulating immunosuppressive pathways, thereby promoting tumor progression and metastasis. Conversely, they can also transport and release immunomodulatory factors that stimulate the activation and regulation of the immune system, enhancing the body's capacity to combat malignant diseases. This dual functionality of EVs presents promising avenues and targets for tumor immunotherapy. By examining the biological characteristics of EVs and their influence on tumor immunity, novel therapeutic strategies can be developed to improve the efficacy and relevance of cancer treatment. This review delineates the complex role of EVs in tumor immunomodulation and explores their potential implications for cancer therapeutic approaches, aiming to establish a theoretical foundation and provide practical insights for the advancement of future EVs-based cancer immunotherapy strategies.
细胞外囊泡(EVs)是细胞分泌的纳米级囊泡,近年来因其在肿瘤免疫调节中的作用而备受关注。这些囊泡通过运输蛋白质、核酸和其他生物活性物质促进细胞间通讯,并且在肿瘤发展和免疫逃逸机制中发挥双重作用。具体而言,EVs可通过损害免疫细胞功能或调节免疫抑制途径来帮助肿瘤细胞逃避免疫监视和攻击,从而促进肿瘤进展和转移。相反,它们还可运输和释放刺激免疫系统激活和调节的免疫调节因子,增强机体对抗恶性疾病的能力。EVs的这种双重功能为肿瘤免疫治疗提供了有前景的途径和靶点。通过研究EVs的生物学特性及其对肿瘤免疫的影响,可以开发新的治疗策略,以提高癌症治疗的疗效和针对性。本综述阐述了EVs在肿瘤免疫调节中的复杂作用,并探讨了它们对癌症治疗方法的潜在影响,旨在为未来基于EVs的癌症免疫治疗策略的发展奠定理论基础并提供实践见解。
Mol Cancer. 2025-2-14
Front Immunol. 2025-3-4
Front Immunol. 2025-2-26
Nat Immunol. 2021-5
J Exp Clin Cancer Res. 2025-5-2
Int Immunopharmacol. 2024-9-30
J Exp Clin Cancer Res. 2025-7-21
Nat Nanotechnol. 2025-1
J Exp Med. 2024-7-1
J Mater Chem B. 2024-4-24
Funct Integr Genomics. 2024-2-16